PDGFC facilitates enzalutamide resistance in prostate cancer through activation of the Rap1-MAPK pathway
Our results confirmed the pivotal role of PDGFC in the development of enzalutamide resistance in PCa. Targeting PDGFC or PDGFC mediate Rap1-MAPK pathway may serve as a promising therapeutic strategy for EnzaR PCa.
Authors
- Saipeng Chen (ORCID: https://orcid.org/0000-0002-8840-1153)
- Rongrong Ni
- Heting Liu (ORCID: https://orcid.org/0000-0002-0321-347X)
- Guojing Song (ORCID: https://orcid.org/0000-0003-0679-4422)
- Wenhao Shen (ORCID: https://orcid.org/0000-0002-4410-128X)
- Gang Huang (ORCID: https://orcid.org/0000-0001-6850-940X)
- Bingqian Deng
- Dan Zhong (ORCID: https://orcid.org/0000-0001-9025-9339)
- Langlang Xie
- Youxin Liu
Institutions
- Army Medical University (CN)
- Southwest Hospital (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1007/s00432-025-06276-w
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00